The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Historical Look at the Characterization of Lupus as a Systemic Disease

A Historical Look at the Characterization of Lupus as a Systemic Disease

October 18, 2018 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Salmon provides an example of a lupus patient who has erosive arthritis and does not have nephritis. Such a patient will get treated like a patient with rheumatoid arthritis, because her joints are the main problem. Dr. Salmon says, “TNF inhibitors are actually effective in lupus patients with erosive arthritis.”

You Might Also Like
  • Systemic Lupus Erythematosus
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Studies Examine Peripheral Nervous System Disease in Lupus Patients
Explore This Issue
October 2018
Also By This Author
  • Telehealth Brings Opportunities to Enhance Patient Care

She argues that rheumatologists have been quite limited in their ability to target disease mechanisms in lupus (other than through broad immunosuppression), although some important drugs that affect key lupus-related pathways are in phase 3 trials, such as interferon-alpha receptor antibodies and JAK-STAT inhibitors. She notes, “At this point we treat the patient’s disease manifestations as best as we can.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Indeed, physicians sometimes use drugs off label to take advantage of the mechanistic overlap of diseases on the rheumatic spectrum. “Hydroxychloroquine is a drug used for lupus patients, but we are now using it for other autoimmune conditions, such as for antiphospholipid syndrome and in pregnant anti-Ro-positive patients to prevent neonatal lupus and congenital heart block,” Dr. Salmon says. “Because these diseases blend into each other clinically, and perhaps pathogenetically, these therapies are used more generally based on plausible mechanism.”

Criteria Under Review

New criteria for lupus that have been supported by the ACR and EULAR are currently under review. These new criteria aim to provide greater sensitivity and specificity for the disease. Under the new criteria, a positive ANA is a necessary condition for a SLE diagnosis. For Dr. Kaposi, a rash was a necessary criterion.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Salmon says, “The ACR criteria for lupus are good for trials, but we don’t treat patients based on the criteria. There are patients with three, not four, criteria for lupus who rheumatologists believe have the disease and treat them accordingly.” She notes the effort to revise is important for the goal of appropriately identifying groups for lupus trials. “We have to keep revisiting how we lump and split, how we classify patients, because we want to find good therapies. And if we enroll patients that are too variable in their mechanism of disease in a trial, then the overall trial will fail, even if the drug would be amazing for an important subset of patients.”

In one sense the effort can be viewed as a continuation of the work done over 140 years ago by Dr. Kaposi. His work set the stage for further classification, understanding and, ultimately, treatment of the disease, a process that is still ongoing.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Classification Criteria, Dr. Moriz Kaposi, History, Lost & FoundIssue: October 2018

You Might Also Like:
  • Systemic Lupus Erythematosus
  • Tabalumab Modestly Effective in Systemic Lupus Erythematosus
  • Studies Examine Peripheral Nervous System Disease in Lupus Patients
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)